Bestinvest Logo
Why us
Planning ahead
Insights
fund

AXA Framlington Biotech Z

Bestinvest LogoSpecialist biotech fund with a large exposure to US listed companies.

PRICE (INC)

175.6p

PRICE (ACC)

511.3p

INITIAL CHARGE

0%

ANNUAL MANAGEMENT CHARGE

0.75%

ONGOING CHARGE

0.83%

YIELD

0%

1 YEAR
0.47%

Prices as at 10 Aug 2022.

We don’t currently provide commentary on this fund.

Past performance is not an indication of future performance.

Capital at risk.

The fund targets long term capital appreciation by investing principally in the equity securities of companies in the biotechnology, genomic and medical research industries. The fund invests worldwide in companies of all sizes, but the bulk of the portfolio will consist of US stocks, reflecting the location of much of the biotech industry.

Fund summary

SectorSpecialist
StructureUNIT TRUST
LaunchedApril 2012
Size£396m
Yield0%
Charging BasisIncome
Dividends paid30 Apr, 31 Oct

Charges

Standard Initial Charge0%
Initial Charge Via BestInvest0%
Additional Bid/Offer Spread0%
Annual Management Charge0.75%
Ongoing Charges Figure0.83%

Investment Process

The fund’s investment universe consists of around 1000 public quoted biotech companies worldwide. These are filtered for such factors as ability to fund future operations and trading liquidity, reducing the universe to around 400-500 names which undergo qualitative analysis. Companies are assessed through contact with company management, attendance at conferences, consultation with industry experts and through consultation with other AXA Framlington fund managers. The manager targets companies with characteristics including: a strong product pipeline; quality management; robust clinical trial processes; market leading technologies. The process can also incorporate investment themes, such as the effects of the bird flu outbreak. Company sizes in the portfolio may be adjusted to reflect market conditions, with large, profitable companies favoured in more volatile environments.

The information on this website is not intended to be advice or a recommendation to buy, sell or hold any investment mentioned. The value of investments and the income from them can go down as well as up and you may not get back the amount invested.

Past performance is not a guide to future performance. View full risk warning